Yahoo Finance- Breakout 12/10/13 Twitter Sets New Highs: Here Are 3 Reasons Why It’s Going Higher
By Matt Nesto | Breakout –
another nice upgrade
Fly On the Wall
Stock Market & Financial Investment News
December 10, 2013
06:26 EDT GERN Geron upgraded to Buy from Hold at NeedhamNeedham upgraded Geron following presentation of Imetelstat data at the ASH meeting that exceeded expectations. Price target is $10.
As previously disclosed, Celldex will issue a press release in concordance with the presentation on November 24 and will host a conference call to review the data on Monday, November 25 at 8:30 am ET.
PHILLIPSBURG, N.J., Nov 11, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (CLDX) "ReACT: a Phase 2 Study of Rindopepimut Vaccine (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma" Comprehensive, updated data from the study will be presented by David Reardon, MD, Clinical Director, Center for Neuro-Oncology, Dana Farber Cancer Center and Associate Professor of Medicine, Harvard Medical School during an oral session on Sunday, November 24 from 10:20 am to 12:00 pm PT at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in conjunction with the 18th Annual Meeting of the Society for Neuro-Oncology in San Francisco, CA. As previously disclosed, Celldex will issue a press release in concordance with the presentation on November 24 and will host a conference call to review the data on Monday, November 25 at 8:30 am ET.
mad I'm not in but with good results CLDX will continue climbing all day Monday.
$CLDX Celldex ( CLDX ) Monday Catalyst : Phase II Study Announced on CLDX Lead Drug CDX-110. Upcoming Data Will Take CLDX To $35 +